Overview

Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

Status:
Unknown status

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to determine the impact of adjunctive cilostazol on platelet inhibition in carriers and non-carriers of the loss-of-function CYP2C19 allele.

Phase:

Phase 3

Details

Lead Sponsor:

Gyeongsang National University Hospital

Treatments:

Aspirin
Cilostazol
Clopidogrel
Ticlopidine